What is lymphangiomyomatosis (LAM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Lymphangioleiomyomatosis (LAM)?

Lymphangioleiomyomatosis (LAM) is a rare, systemic neoplastic disease characterized by abnormal proliferation of smooth muscle-like cells (LAM cells) that causes progressive cystic destruction of the lungs, lymphatic abnormalities, and abdominal tumors, occurring almost exclusively in women of reproductive age. 1, 2

Epidemiology and Patient Population

LAM presents in two distinct forms:

  • Sporadic LAM (S-LAM): Affects approximately 1 in 400,000 adult females 2
  • TSC-associated LAM (TSC-LAM): Occurs in 30-40% of adult females with tuberous sclerosis complex 2
  • Exceptionally rare in males and children 2

Pathophysiology

The disease results from mutations in TSC1 or TSC2 genes, leading to:

  • Loss of function of hamartin and tuberin proteins
  • Constitutive activation of the mechanistic target of rapamycin (mTOR) pathway 2, 3
  • Uncontrolled proliferation and metastatic spread of LAM cells through lymphatic channels 4
  • Production of lymphangiogenic growth factors (VEGF-C and VEGF-D) 4
  • Progressive cystic remodeling and destruction of lung parenchyma

The disease behaves as a low-grade metastasizing neoplasm with cells spreading primarily through lymphatic channels, often originating from the pelvis and involving abdominal, axial, and retroperitoneal lymph nodes. 4

Clinical Manifestations

Pulmonary Features

  • Progressive dyspnea (most common presenting symptom) 2, 5
  • Recurrent spontaneous pneumothorax (characteristic presentation) 2, 5
  • Chylous pleural effusions
  • Occasional hemoptysis 2
  • Reduced flow rates (FEV₁) and diffusion capacity on pulmonary function testing 3

Extrapulmonary Manifestations

  • Renal angiomyolipomas (kidney tumors) 2
  • Lymphangioleiomyomas (cystic masses of axial lymphatics causing abdominal/pelvic lymphatic obstruction) 2
  • Chylous ascites
  • Extrapulmonary lymphadenopathy 2
  • Increased frequency of meningiomas 2
  • Lower extremity lymphedema 4

Diagnostic Approach

Imaging

High-resolution computed tomography (HRCT) showing characteristic diffuse thin-walled pulmonary cysts is the cornerstone of diagnosis 2

Pathological Confirmation

When biopsy is performed (lung, lymph nodes, or lymphangioleiomyomas):

  • Characteristic LAM cell morphology
  • Positive immunoreactivity to smooth muscle actin and HMB-45 antibodies 2

Biomarker Testing

For patients with characteristic CT findings but no confirmatory extrapulmonary features, VEGF-D testing is strongly recommended before proceeding to lung biopsy 1. Serum VEGF-D is elevated in approximately 70% of LAM patients and serves as both a diagnostic and prognostic biomarker 4.

Confirmatory Features

  • Tuberous sclerosis complex
  • Angiomyolipomas
  • Chylous pleural effusions or ascites
  • Cystic lymphangioleiomyomas 1

Disease Progression and Prognosis

LAM demonstrates variable clinical features and rates of progression, making prognostication challenging 2. The disease is slowly progressive but can lead to:

  • Respiratory failure requiring oxygen therapy
  • Recurrent complications (pneumothorax, chylous effusions)
  • Need for lung transplantation in advanced cases

Impact on Morbidity, Mortality, and Quality of Life

Without treatment, LAM causes:

  • Progressive respiratory impairment limiting daily activities
  • Recurrent hospitalizations for pneumothorax and effusions
  • Significant reduction in exercise capacity and quality of life
  • Potential respiratory failure and death in advanced disease

The introduction of mTOR inhibitors has fundamentally changed the natural history of LAM, stabilizing lung function and reducing the size of chylous effusions and abdominal tumors, thereby improving both morbidity and quality of life. 1, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.